SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer

Results of a phase II trial evaluating pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide were presented at SGO 2019.

Source: CancerNetwork - March 19, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news